RxDoctor Payments Data

Patrick Williams, MD

Family Medicine · Locust, NCNPI 1891133344

Payments from drug & device makers

$5,040in general payments, 2019–2025

Across 247 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$673
  • Preventric Diagnostics, Inc.$647
  • Boehringer Ingelheim$631
  • AstraZeneca$563
  • Lilly USA, LLC$277
  • AbbVie$267
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,023100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,040 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$122,451
Medicare patients
232
Services billed
2,682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$124,761
JardianceEmpagliflozin80$98,485
EliquisApixaban56$55,795
RybelsusSemaglutide42$50,085
Tresiba Flextouch U-100Insulin Degludec48$33,368
Repatha SureclickEvolocumab40$24,276
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$23,530
MounjaroTirzepatide15$21,482
Tresiba Flextouch U-200Insulin Degludec20$19,094
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$17,141
LinzessLinaclotide19$15,199
XareltoRivaroxaban11$9,307
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$9,238
Advair HfaFluticasone Propion/Salmeterol15$9,227
Atorvastatin Calcium487$6,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$673$174,846138 claims
Boehringer IngelheimJardiance, Stiolto Respimat$631$107,723103 claims
PfizerEliquis$102$55,79556 claims
AstraZenecaBreztri Aerosphere$563$23,53034 claims
Lilly USA, LLCMounjaro$277$21,48215 claims
GSKTrelegy Ellipta$36$17,14123 claims
AbbVieLinzess, Synthroid$267$16,80034 claims
Johnson & JohnsonXarelto$95$9,30711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Locust

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →